News & Events

The information in our press releases should be considered accurate only as of the date of the press release. We disclaim any obligation to supplement or update the information in these press releases.

Impel NeuroPharma Announces Pricing of $80.0 Million Initial Public Offering

SEATTLE, April 22, 2021 — Impel NeuroPharma, Inc. (Impel), a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, today announced the pricing of its…

READ MORE

IMPEL NEUROPHARMA ANNOUNCES KEY MANAGEMENT TEAM APPOINTMENTS AS COMPANY ADVANCES TOWARD COMMERCIALIZATION IN 2021

Leonard S. Paolillo Appointed as Chief Commercial Officer, Gerald F. Penn Appointed as Vice President, Market Access & Trade Significant Leadership Experience Continues Build Out of Impel’s Commercial Strategy, Infrastructure and Market Access Capabilities as Company Advances Go-To-Market Strategy for…

READ MORE

IMPEL NEUROPHARMA PARTNERS WITH VEEVA SYSTEMS TO BUILD INTEGRATED, DIGITAL-FIRST COMMERCIAL FOUNDATION

Impel adopting Veeva software, data, and consultingto accelerate pre-launch planning and digital-first commercial execution SEATTLE and PLEASANTON, CA — February 10, 2021 — Impel NeuroPharma and Veeva Systems (NYSE: VEEV) today announced a strategic partnership as Impel continues advancing its…

READ MORE

IMPEL NEUROPHARMA ANNOUNCES U.S. FOOD & DRUG ADMINISTRATION ACCEPTANCE OF NEW DRUG APPLICATION FOR INP104 FOR THE ACUTE TREATMENT OF MIGRAINE

FDA Conditionally Accepts Trade Name, TRUDHESA™, Pending Approval of the NDA, and Sets PDUFA Goal Date of September 6, 2021 Company’s Lead Candidate is Based on Impel’s Proprietary Precision Olfactory Delivery (POD®) Technology, and is the First and Only Delivery…

READ MORE

IMPEL NEUROPHARMA ANNOUNCES FDA SUBMISSION OF NEW DRUG APPLICATION FOR INP104 FOR THE ACUTE TREATMENT OF MIGRAINE

~The INP104 New Drug Application is Supported by Results from the Phase 3 STOP 301 Study~ ~Dihydroergotamine mesylate (DHE) is Administered via Impel’s Proprietary Precision Olfactory Delivery (POD®) Technology, the First and Only Delivery System to Utilize the Vascular-Rich Upper…

READ MORE

IMPEL NEUROPHARMA PRESENTS DATA FROM PIVOTAL PHASE 3 REGISTRATION STUDY OF INP104 FOR THE TREATMENT OF ACUTE MIGRAINE AT 2020 MIGRAINE TRUST VIRTUAL SYMPOSIUM

66.3% of Patients Reported Pain Relief Within Two Hours of Treatment with Rapid Uptake via the Upper Nasal Space Resulting in Onset of Relief as Early as 15 Minutes for Some Patients Data Suggest Use of Impel’s Proprietary Precision Olfactory…

READ MORE

IMPEL NEUROPHARMA ANNOUNCES PUBLICATION OF POSITIVE RESULTS OF SNAP 101 STUDY FOR INP105 FOR THE TREATMENT OF ACUTE AGITATION IN THE JOURNAL OF CLINICAL PSYCHIATRY

Study Shows INP105 Achieves Rapid Absorption Which May Provide An Effective, Convenient, & Noninvasive Future Alternative for Treating Acute Agitation In the Home, Community, or Hospital Setting INP105 is a Powder Formulation of Olanzapine, the Gold Standard Treatment for Acute…

READ MORE

IMPEL NEUROPHARMA PRESENTS DATA FROM INP104 CLINICAL PROGRAM IN ACUTE MIGRAINE AT THE 2020 AMERICAN HEADACHE SOCIETY (AHS) VIRTUAL ANNUAL SCIENTIFIC MEETING

Four Scientific Poster Presentations Support the Potential of INP104 to Fulfill Key Unmet Needs and If Approved, Become a Transformative New Therapeutic Option for Acute Migraine Additional Data from STOP 301, the Company’s Pivotal Phase 3 Study of INP104 for…

READ MORE

IMPEL NEUROPHARMA ANNOUNCES PRIMARY OBJECTIVES MET IN PIVOTAL PHASE 3 REGISTRATION STUDY OF INP104 FOR THE TREATMENT OF ACUTE MIGRAINE

Exploratory Efficacy Data Reveal INP104 Resulted in Pain Relief in 66.3% of Patients and Pain Freedom in 38% of Patients at Two Hours After First Dose; Additionally, 16.3% of Patients Reported They Gained Initial Relief as Early as 15 Minutes…

READ MORE

Impel NeuroPharma Announces Leadership Transition, Chairman Adrian Adams’ Role Expanded To Chairman and CEO

SEATTLE, May 5, 2020 — Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced an expanded role of…

READ MORE